Computer-Aided Drug Design and Drug Discovery: A Prospective Analysis

In the dynamic landscape of drug discovery, Computer-Aided Drug Design (CADD) emerges as a transformative force, bridging the realms of biology and technology. This paper overviews CADDs historical evolution, categorization into structure-based and ligand-based approaches, and its crucial role in ra...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Pharmaceuticals (Basel, Switzerland) Jg. 17; H. 1; S. 22
Hauptverfasser: Niazi, Sarfaraz K., Mariam, Zamara
Format: Journal Article
Sprache:Englisch
Veröffentlicht: Switzerland MDPI AG 22.12.2023
MDPI
Schlagworte:
Algorithms
Artificial intelligence
Biology
Chemoinformatics
Computer simulation
Computer-Aided Drug Design (CADD)
Drug discovery
Hydrogen bonds
Kinases
Ligands
Machine learning
Machine Learning and Artificial Intelligence (AI)
Metabolism
molecular docking
molecular modeling
Pharmaceutical industry
Pharmacokinetics
Proteins
R&D
Research & development
Review
Germany
Computer-Aided Drug Design (CADD)
molecular docking
drug discovery
molecular modeling
target identification
Chemoinformatics
Machine Learning and Artificial Intelligence (AI)
ISSN:1424-8247, 1424-8247
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:In the dynamic landscape of drug discovery, Computer-Aided Drug Design (CADD) emerges as a transformative force, bridging the realms of biology and technology. This paper overviews CADDs historical evolution, categorization into structure-based and ligand-based approaches, and its crucial role in rationalizing and expediting drug discovery. As CADD advances, incorporating diverse biological data and ensuring data privacy become paramount. Challenges persist, demanding the optimization of algorithms and robust ethical frameworks. Integrating Machine Learning and Artificial Intelligence amplifies CADDs predictive capabilities, yet ethical considerations and scalability challenges linger. Collaborative efforts and global initiatives, exemplified by platforms like Open-Source Malaria, underscore the democratization of drug discovery. The convergence of CADD with personalized medicine offers tailored therapeutic solutions, though ethical dilemmas and accessibility concerns must be navigated. Emerging technologies like quantum computing, immersive technologies, and green chemistry promise to redefine the future of CADD. The trajectory of CADD, marked by rapid advancements, anticipates challenges in ensuring accuracy, addressing biases in AI, and incorporating sustainability metrics. This paper concludes by highlighting the need for proactive measures in navigating the ethical, technological, and educational frontiers of CADD to shape a healthier, brighter future in drug discovery.
Bibliographie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
ISSN:1424-8247
1424-8247
DOI:10.3390/ph17010022